Skip to main content

Inovio Pharma(INO-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.7200
Day High1.7700
Open:1.7200
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Inovio Pharma

Select a category then submit the form to load news
Motley Fool
Is Inovio Pharmaceuticals Stock Going to $0?
Tipranks
Inovio Extends Series A Warrants, Enhancing Capital Flexibility
Newsfile
INO Investor Notice: Levi & Korsinsky Investigates Inovio Pharmaceuticals, Inc. for Securities Law Violations
Tipranks
Piper Sandler Reaffirms Their Buy Rating on Inovio Pharmaceuticals (INO)
Tipranks
FDA Accepts Inovio’s BLA for INO-3107 Review
Tipranks
Inovio announces U.S. FDA accepted BLA for INO-3107
Tipranks
Inovio Pharmaceuticals (INO) Receives a Buy from Piper Sandler
Tipranks
Inovio Pharmaceuticals’ Earnings Call: Milestones Amid Financial Challenges
Tipranks
Inovio Pharmaceuticals (INO) Receives a Buy from Oppenheimer
Tipranks
Inovio Pharmaceuticals Reports Q3 2025 Financial Results
Zacks Investment Research
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug
Tipranks
Oppenheimer Remains a Buy on Inovio Pharmaceuticals (INO)
Newswire.ca
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
Tipranks
Jefferies Sticks to Their Buy Rating for Inovio Pharmaceuticals (INO)
Tipranks
Citizens JMP Sticks to Its Buy Rating for Inovio Pharmaceuticals (INO)
Tipranks
Inovio Pharmaceuticals (INO) Receives a Buy from Piper Sandler
Motley Fool
Inovio Cuts Q2 Losses by 27%
Tipranks
Inovio Pharmaceuticals Announces Public Offering Agreement
Tipranks
RBC Capital Sticks to Its Hold Rating for Inovio Pharmaceuticals (INO)
Tipranks
Options Volatility and Implied Earnings Moves Today, May 13, 2025
Tipranks
Options Volatility and Implied Earnings Moves This Week, May 12 – May 15, 2025
Tipranks
RBC Capital Sticks to Their Hold Rating for Inovio Pharmaceuticals (INO)
Tipranks
JMP Securities Sticks to Their Buy Rating for Inovio Pharmaceuticals (INO)
Motley Fool
Inovio Pharmaceuticals (INO) Q4 2024 Earnings Call Transcript
Tipranks
Options Volatility and Implied Earnings Moves Today, March 18, 2025
Tipranks
Options Volatility and Implied Earnings Moves This Week, March 17 – March 21, 2025
Motley Fool
Inovio Pharmaceuticals (INO) Q3 2024 Earnings Call Transcript
GlobeNewswire
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
Motley Fool
Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcript
Barchart
5 Analyst-Approved Stocks Set to Join the Russell Microcap Index
Savings - Savings Piggybank White Background
Motley Fool
Better Buy: Inovio Pharmaceuticals vs. Novavax
Motley Fool
Inovio Pharmaceuticals (INO) Q1 2024 Earnings Call Transcript

Profile

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.